C07J 51/00
Normal steroids with unmodified cyclopentahydrophenanthrene skeleton not provided for in groups c07j1/00
Official title: Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
C07J51/00 (Normal steroids with unmodified cyclopentahydrophenanthrene skeleton not provided for in groups c07j1/00) appears on 601 US grants and 386 published applications in this corpus.
Search patents in C07J- Granted patents
- 601
- Published applications
- 386
- Assignees
- 337
- Inventors
- 1,382
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 7 | 0 |
| 1977 | 6 | 0 |
| 1978 | 15 | 0 |
| 1979 | 7 | 0 |
| 1980 | 14 | 0 |
| 1981 | 7 | 0 |
| 1982 | 12 | 0 |
| 1983 | 8 | 0 |
| 1984 | 8 | 0 |
| 1985 | 13 | 0 |
| 1986 | 7 | 0 |
| 1987 | 9 | 0 |
| 1988 | 7 | 0 |
| 1989 | 8 | 0 |
| 1990 | 23 | 0 |
| 1991 | 19 | 0 |
| 1992 | 19 | 0 |
| 1993 | 18 | 0 |
| 1994 | 15 | 0 |
| 1995 | 23 | 0 |
| 1996 | 20 | 0 |
| 1997 | 33 | 0 |
| 1998 | 29 | 0 |
| 1999 | 14 | 0 |
| 2000 | 18 | 0 |
| 2001 | 11 | 2 |
| 2002 | 10 | 3 |
| 2003 | 4 | 7 |
| 2004 | 5 | 8 |
| 2005 | 7 | 8 |
| 2006 | 3 | 7 |
| 2007 | 1 | 10 |
| 2008 | 2 | 5 |
| 2009 | 3 | 2 |
| 2010 | 4 | 9 |
| 2011 | 6 | 5 |
| 2012 | 4 | 8 |
| 2013 | 1 | 13 |
| 2014 | 4 | 17 |
| 2015 | 13 | 14 |
| 2016 | 8 | 28 |
| 2017 | 24 | 27 |
| 2018 | 11 | 27 |
| 2019 | 27 | 26 |
| 2020 | 18 | 31 |
| 2021 | 25 | 26 |
| 2022 | 14 | 22 |
| 2023 | 10 | 24 |
| 2024 | 8 | 23 |
| 2025 | 14 | 23 |
| 2026 | 5 | 11 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof6 Oct 2026US 12,753,204 B2Enanta Pharmaceuticals, Inc.
- Modular synthesis of 1,2-azaborines via ring-opening BN-isostere benzannulation18 Aug 2026US 12,709,624 B2The University of Chicago
- Bile acid-GCPII inhibitor conjugates to treat inflammatory diseases, including inflammatory bowel disease (IBD)4 Aug 2026US 12,698,306 B2Institute of Organic Chemistry and Biochemistry of the AS CR, V.V.I.
- Process for preparing B-[(7a, 1713)-17-hydroxy-7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-trien-3-yl]-boronic acid14 Apr 2026US 12,600,745 B2Industriale Chimica S.R.L.
- 2-methoxyestradiol derivatives and medical uses thereof10 Mar 2026US 12,570,685 B2Institut Pasteur Korea
- Bicyclic abasic nucleic acid analogs and oligomeric compounds prepared therefrom9 Jul 2026US 2026/0193653 A1Shanghai Argo Biopharmaceutical Co., Ltd.
- Preparation and uses of obeticholic acid18 Jun 2026US 2026/0167663 A1Intercept Pharmaceuticals, Inc.
- Androstane Derivatives with Activity as Pure or Predominantly Pure Stimulators of SERCA2a for the Treatment of Heart Failure7 May 2026US 2026/0125415 A1Seismic Pharmaceuticals Operations LLC
- Neurosteroid compounds and methods for their preparation and use in treating central nervous system disorders30 Apr 2026US 2026/0116913 A1The Texas A&M University System
- Ionizable cationic lipids incorporating silicon: synthesis and lnp formulation23 Apr 2026US 2026/0109721 A1Aldexchem Kft.
Most cited
By later US patents
- Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof518US 5,550,111 ATemple University of the Commonwealth System of Higher Education · 1996
- Thiol-derivatized nucleosides365US 5,578,718 AIsis Pharmaceuticals, Inc. · 1996
- Cholesteryl modified oligonucleotides341US 4,958,013 ANorthwestern University · 1990
- Steroid modified oligonucleotides301US 5,416,203 ANorthwestern University · 1995
- Oligonucleotide having enhanced binding affinity276US 5,486,603 AGilead Sciences, Inc. · 1996